Genmab — Februar 2019
-
apparantly for TV they "are also developing a test to pick out the patients most likely to respond". I had not seen that yet. That is interesting, if that works and they only target those pre selected patients, response rate could improve significantly. (from https://www.thethings.com/new-cancer-drug-successfully-treats-six-different-types-lethal-tumors/ )
-
Ved 3 mia. Plus sandsynlig milestone på 100 mio$
-
Derfor ca 3,5 mia D.kr ved 3
-
Mia salg og dollar 6,5
-
E L - thats the clever way to do it if possible. Lets hope they take the same way forward with Enapotamab - BergenBio for instance is developing a biomarker companion diagnostic for AXL and its seems to work. They will use it in the coming possible pivotal trials
-
-
jeg har lagt lidt recepttal og forecasts for dara I debatten
-
jep - problemet med approvals (rent forecastmæssigt), er at de typisk giver et bump. Og det er lidt svært at få ind i tallene
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind